Mosaic Biosciences and Tango Biosciences add phage display to critical reagent discovery

Mosaic Biosciences and Tango Biosciences announced a strategic partnership on July 21, 2026, to speed discovery of critical reagents, including anti-idiotype antibodies, for biopharma programs. The collaboration combines Tango’s phage display libraries with Mosaic’s downstream development and characterization services, with some binders available in as little as four weeks.

Why it matters: - Biopharma teams need faster critical reagents for PK/PD assays, immunogenicity testing and clinical-stage programs. - The partnership is designed to shorten timelines for anti-idiotype antibodies, ADA positive controls and tool antibodies. - Mosaic Biosciences says the model gives clients a faster and more flexible in vitro option than traditional in vivo approaches that can take several months.

What happened: - Mosaic Biosciences announced a strategic partnership with Tango Biosciences on July 21, 2026. - The agreement expands Mosaic’s critical reagent discovery portfolio with phage display-based in vitro discovery. - The collaboration gives Mosaic access to Tango Biosciences’ high-diversity phage display libraries in Fab, scFv, VHH and monobody formats. - The companies said high-quality selective binders can be delivered in as short as four weeks from antigen to validated binders.

The details: - Tango Biosciences brings more than 35 antibody and peptide libraries. - Tango Biosciences says its success rate exceeds 95%. - The company’s phage display platform supports rapid screening across multiple formats and targets. - Mosaic’s downstream capabilities include protein engineering, assay development, Carterra SPR characterization and tech transfer. - Mosaic will serve as the primary point of contact for integrated critical reagent programs that use phage display discovery. - Tango Biosciences will provide library access and phage display execution. - Downstream characterization, assay development and tech transfer will remain within Mosaic’s integrated service model. - Mosaic Biosciences is based in Boulder, Colorado. - Tango Biosciences was founded in 2016 from the laboratory of Dr. Brian Kay at the University of Illinois Chicago. - Mosaic’s broader discovery toolkit also includes in vitro display, single B cell methods, transgenic animal platforms and AI-enabled screening approaches.

Between the lines: - The partnership blends discovery and downstream validation under one workflow, which can reduce handoffs for development-stage teams. - The deal also reflects continued demand for non-animal discovery methods in reagent development. - Mosaic’s platform-agnostic positioning suggests the company is trying to match each target with the fastest workable discovery route. - Tango Biosciences is leaning on its library depth and phage display expertise to reach clients that want more reproducible outputs.

What's next: - The partnership is effective immediately. - Clients seeking integrated critical reagent programs can work through Mosaic Biosciences as the lead contact. - The companies plan to use the combined platform to move hits from discovery toward validated, assay-ready reagents. - More information is available on Mosaic Biosciences' website. - Mosaic also links to its LinkedIn page and YouTube channel.